⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Acerand Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Acerand Therapeutics
↗Carmel, USA / Shanghai, China
Acerand Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of innovative, best-in-class, and first-in-class small-molecule therapies. The company primarily targets oncology, immunology, and metabolic diseases, leveraging advanced computational chemistry and drug design platforms.
Founded in 2020 by industry veterans with support from Lilly Asian Ventures, the company maintains a global operational strategy with facilities in Shanghai, China, and Indianapolis, USA. Acerand utilizes a data-driven approach to drug discovery, integrating internal expertise with external CRO partnerships to advance its pipeline of novel chemical entities.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2020
Ownership:private
Status:operating
FUNDING
Stage:Private
Investors:Lilly Asian Ventures
PIPELINE
Stage:Phase 1/2
Lead Drug Stage:Phase 1/2
Modalities:Small molecule
Active Trials:2
Trial Phases:Phase 1: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:XtalPi (AI-driven drug discovery collaboration)
COMPETITION
Position:Emerging
Competitors:BeiGene, MacroGenics, Harbour BioMed
LINKS
Website:acerand.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Acerand Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.